

NCT02431442 Raw comparison:

Summary:
CHIA has 45 criteria while your personal folder has 47 criteria
Total found criteria: 45/45
Total not Found: 0/45
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Able to provide voluntary written informed consent │ Able to provide voluntary written informed consent │
│ with comprehension of all aspects of the protocol  │ with comprehension of all aspects of the protocol  │
│ prior to any study procedures                      │ prior to any study procedures                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Healthy obese male and female volunteers aged 18   │ Healthy obese male and female volunteers aged 18   │
│ to 55 years inclusive Heterozygous subjects may be │ to 55 years inclusive Heterozygous subjects may be │
│ 18 to 65 years inclusive                           │ 18 to 65 years inclusive                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ In good general health without significant medical │ In good general health without significant medical │
│ history physical examination findings or clinical  │ history physical examination findings or clinical  │
│ laboratory abnormalities                           │ laboratory abnormalities                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Body Mass Index of 30-40 kg/m2 inclusive           │ Body Mass Index of 30-40 kg/m2 inclusive           │
│ Heterozygous subjects may have a broader BMI range │ Heterozygous subjects may have a broader BMI range │
│ to be eligible heterozygous subjects may have a    │ to be eligible heterozygous subjects may have a    │
│ BMI 27 -55 kg/ m2 inclusive                        │ BMI 27 -55 kg/ m2 inclusive                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Stable body weight during the previous 6 months    │ Stable body weight during the previous 6 months    │
│ based on Investigator judgment                     │ based on Investigator judgment                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Blood pressure <140/90 mmHg at Screening and D-1   │ Blood pressure \<140/90 mmHg at Screening and D-1  │
│ Measurement may be repeated within 24 hours based  │ Measurement may be repeated within 24 hours based  │
│ on Investigator judgment                           │ on Investigator judgment                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Females must not be pregnant and must have a       │ Females must not be pregnant and must have a       │
│ negative serum pregnancy test result at the        │ negative serum pregnancy test result at the        │
│ Screening Visit and Day -1                         │ Screening Visit and Day -1                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Females of childbearing potential must agree to be │ Females of childbearing potential must agree to be │
│ abstinent or else use any two of the following     │ abstinent or else use any two of the following     │
│ medically acceptable forms of contraception from   │ medically acceptable forms of contraception from   │
│ the Screening Period through the Final Study Visit │ the Screening Period through the Final Study Visit │
│ hormonal condom with spermicidal jelly diaphragm   │ hormonal condom with spermicidal jelly diaphragm   │
│ or cervical cap with spermicidal jelly or IUD      │ or cervical cap with spermicidal jelly or IUD      │
│ Hormonal contraception must have started at least  │ Hormonal contraception must have started at least  │
│ 3 months prior to screening A female whose male    │ 3 months prior to screening A female whose male    │
│ partner has had a vasectomy must agree to use one  │ partner has had a vasectomy must agree to use one  │
│ additional form of medically acceptable            │ additional form of medically acceptable            │
│ contraception Subjects must agree to practice the  │ contraception Subjects must agree to practice the  │
│ above birth control methods for 30 days from the   │ above birth control methods for 30 days from the   │
│ final visit as a safety precaution                 │ final visit as a safety precaution                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Females of non-childbearing potential defined as   │ Females of non-childbearing potential defined as   │
│ surgically sterile (status post hysterectomy       │ surgically sterile (status post hysterectomy       │
│ bilateral oophorectomy or bilateral tubal          │ bilateral oophorectomy or bilateral tubal          │
│ ligation) or post-menopausal for at least 12       │ ligation) or post-menopausal for at least 12       │
│ months (and confirmed with a screening FSH level   │ months (and confirmed with a screening FSH level   │
│ in the post-menopausal range) do not require       │ in the post-menopausal range) do not require       │
│ contraception during the study                     │ contraception during the study                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Males with female partners of childbearing         │ Males with female partners of childbearing         │
│ potential must agree to use two medically          │ potential must agree to use two medically          │
│ acceptable forms of contraception as described     │ acceptable forms of contraception as described     │
│ above with one of the two forms being condom with  │ above with one of the two forms being condom with  │
│ spermicide from the Screening Period through the   │ spermicide from the Screening Period through the   │
│ Final Study Visit Males with female partners of    │ Final Study Visit Males with female partners of    │
│ childbearing potential who themselves are          │ childbearing potential who themselves are          │
│ surgically sterile (status post vasectomy) must    │ surgically sterile (status post vasectomy) must    │
│ agree to use condoms with spermicide over the same │ agree to use condoms with spermicide over the same │
│ period of time Male subjects must agree to         │ period of time Male subjects must agree to         │
│ practice the above birth control methods for 30    │ practice the above birth control methods for 30    │
│ days from the final visit as a safety precaution   │ days from the final visit as a safety precaution   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Fasting blood glucose >126 mg/dL at screening      │ Fasting blood glucose \>126 mg/dL at screening     │
│ Heterozygous subjects will be excluded for a       │ Heterozygous subjects will be excluded for a       │
│ fasting blood glucose >140 mg/dL                   │ fasting blood glucose \>140 mg/dL                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Resting heart rate <45 bpm or >90 bpm at screening │ Resting heart rate \<45 bpm or \>90 bpm at         │
│                                                    │ screening                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Abnormal thyroid stimulating hormone (TSH) or      │ Abnormal thyroid stimulating hormone (TSH) or      │
│ thyroxine (T4) levels on screening                 │ thyroxine (T4) levels on screening                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Elevated ALT or serum creatinine on screening or   │ Elevated ALT or serum creatinine on screening or   │
│ any clinically significant abnormalities on        │ any clinically significant abnormalities on        │
│ screening laboratory tests as determined by the    │ screening laboratory tests as determined by the    │
│ Investigator                                       │ Investigator                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of medically treated diabetes or of        │ History of medically treated diabetes or of        │
│ treated or medically diagnosed hypertension        │ treated or medically diagnosed hypertension        │
│ Heterozygous subjects who have diagnosed           │ Heterozygous subjects who have diagnosed           │
│ hypertension and are well controlled on treatment  │ hypertension and are well controlled on treatment  │
│ (Refer to Exclusion Criteria 20 below) are         │ (Refer to Exclusion Criteria 20 below) are         │
│ eligible                                           │ eligible                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence of a skin lesion suspicious for           │ Presence of a skin lesion suspicious for           │
│ malignancy unless excised prior to Day 1           │ malignancy unless excised prior to Day 1           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of malignancy except for treated cervical  │ History of malignancy except for treated cervical  │
│ carcinoma in situ in the past 5 years              │ carcinoma in situ in the past 5 years              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active or history of any clinically significant    │ Active or history of any clinically significant    │
│ medical condition including renal hepatic          │ medical condition including renal hepatic          │
│ pulmonary gastrointestinal cardiovascular          │ pulmonary gastrointestinal cardiovascular          │
│ genitourinary endocrine immunologic metabolic      │ genitourinary endocrine immunologic metabolic      │
│ neurologic psychiatric or hematological disease    │ neurologic psychiatric or hematological disease    │
│ based on Investigator judgment                     │ based on Investigator judgment                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acute illness or history of illness which in the   │ Acute illness or history of illness which in the   │
│ opinion of the Investigator could pose a threat or │ opinion of the Investigator could pose a threat or │
│ harm to the subject or obscure interpretation of   │ harm to the subject or obscure interpretation of   │
│ laboratory test results or interpretation of study │ laboratory test results or interpretation of study │
│ data                                               │ data                                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Positive hepatitis B surface antigen positive      │ Positive hepatitis B surface antigen positive      │
│ hepatitis C antibody or positive HIV test at       │ hepatitis C antibody or positive HIV test at       │
│ screening or a history of positive testing (e g    │ screening or a history of positive testing (e g    │
│ liver biopsy serology) suggesting acute or chronic │ liver biopsy serology) suggesting acute or chronic │
│ hepatitis                                          │ hepatitis                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Abnormal 12-lead electrocardiogram (ECG) at        │ Abnormal 12-lead electrocardiogram (ECG) at        │
│ screening or pre-dose (Day -1 or Day 1) except     │ screening or pre-dose (Day -1 or Day 1) except     │
│ minor deviations deemed to be of no clinical       │ minor deviations deemed to be of no clinical       │
│ significance by the Investigator                   │ significance by the Investigator                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Received any experimental drugs or devices within  │ Received any experimental drugs or devices within  │
│ 30 days or 5 half lives whichever is longer prior  │ 30 days or 5 half lives whichever is longer prior  │
│ to dosing                                          │ to dosing                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ongoing participation in a prior clinical study at │ Ongoing participation in a prior clinical study at │
│ the time of screening                              │ the time of screening                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Blood donation within 60 days prior to screening   │ Blood donation within 60 days prior to screening   │
│ or intent to donate within 60 days after Final     │ or intent to donate within 60 days after Final     │
│ Study Visit                                        │ Study Visit                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hospitalization for major surgery including but    │ Hospitalization for major surgery including but    │
│ not limited to abdominal thoracic or               │ not limited to abdominal thoracic or               │
│ cardiovascular surgery within the past 3 months    │ cardiovascular surgery within the past 3 months    │
│ prior to screening or for a clinically significant │ prior to screening or for a clinically significant │
│ non-surgical illness based on Investigator         │ non-surgical illness based on Investigator         │
│ judgment within the past 3 months                  │ judgment within the past 3 months                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Planned elective surgery within 30 days of the     │ Planned elective surgery within 30 days of the     │
│ Final Study Visit                                  │ Final Study Visit                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Poor venous access or inability to tolerate        │ Poor venous access or inability to tolerate        │
│ venipuncture                                       │ venipuncture                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of significant drug hypersensitivity or    │ History of significant drug hypersensitivity or    │
│ anaphylaxis                                        │ anaphylaxis                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of hypersensitivity to proteins (e g       │ History of hypersensitivity to proteins (e g       │
│ allergy shots)                                     │ allergy shots)                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of prescription medications on a regular basis │ Use of prescription medications on a regular basis │
│ The last use of any prescription medication must   │ The last use of any prescription medication must   │
│ have been greater than 5 half-lives for the        │ have been greater than 5 half-lives for the        │
│ specific medication or at least 14 days prior to   │ specific medication or at least 14 days prior to   │
│ admission (Day -1) whichever is longer Hormonal    │ admission (Day -1) whichever is longer Hormonal    │
│ contraception is allowed for female subjects       │ contraception is allowed for female subjects       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Heterozygous cohorts Use of prescription           │ Heterozygous cohorts Use of prescription           │
│ medications on a regular basis is not allowed with │ medications on a regular basis is not allowed with │
│ the following exceptions                           │ the following exceptions                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Antihypertensives (<3 medications on a stable dose │ Antihypertensives (\<3 medications on a stable     │
│ for ≥ 30 days)                                     │ dose for ≥ 30 days)                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Statins (dose must be ≤ half the maximum dose must │ Statins (dose must be ≤ half the maximum dose must │
│ be on a stable dose ≥3 months)                     │ be on a stable dose ≥3 months)                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Fibrates (must be on stable dose for ≥3 months)    │ Fibrates (must be on stable dose for ≥3 months)    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Niacin (must be on stable dose for ≥3 months)      │ Niacin (must be on stable dose for ≥3 months)      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Thyroxin (stable dose for ≥ 30 days) The last use  │ Thyroxin (stable dose for ≥ 30 days) The last use  │
│ of any other prescription medication will need     │ of any other prescription medication will need     │
│ follow the criteria for all other cohorts as       │ follow the criteria for all other cohorts as       │
│ outlined above                                     │ outlined above                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of prescription medications not listed above   │ Use of prescription medications not listed above   │
│ may be allowed at the discretion of the            │ may be allowed at the discretion of the            │
│ Investigator upon consultation with Rhythm         │ Investigator upon consultation with Rhythm         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Use of a non-prescription drug and herbal          │ Use of a non-prescription drug and herbal          │
│ substances during the study (through the Final     │ substances during the study (through the Final     │
│ Study Visit) The last dose of any non-prescription │ Study Visit) The last dose of any non-prescription │
│ drug must have been taken greater than 5 half-     │ drug must have been taken greater than 5 half-     │
│ lives for that drug before receiving study drug    │ lives for that drug before receiving study drug    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Inability to attend all study visits or to comply  │ Inability to attend all study visits or to comply  │
│ with protocol requirements including fasting and   │ with protocol requirements including fasting and   │
│ restrictions on alcohol caffeine nicotine and      │ restrictions on alcohol caffeine nicotine and      │
│ concomitant medication intake                      │ concomitant medication intake                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ A significant history of drug/solvent abuse within │ A significant history of drug/solvent abuse within │
│ 5 years of screening or a positive test for drugs  │ 5 years of screening or a positive test for drugs  │
│ of abuse test at screening or on Day -1            │ of abuse test at screening or on Day -1            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Positive alcohol (breath test) or nicotine screen  │ Positive alcohol (breath test) or nicotine screen  │
│ at Screening Visit or Day 1 (positive nicotine     │ at Screening Visit or Day 1 (positive nicotine     │
│ screen does not apply to heterozygous cohort)      │ screen does not apply to heterozygous cohort)      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of alcohol abuse (defined as average       │ History of alcohol abuse (defined as average       │
│ intake of three or more units of alcohol per day)  │ intake of three or more units of alcohol per day)  │
│ within 5 years of the Screening Visit              │ within 5 years of the Screening Visit              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of tobacco or tobacco product use unless   │ History of tobacco or tobacco product use unless   │
│ abstinent for at least one year prior to the       │ abstinent for at least one year prior to the       │
│ Screening Visit This criterion does not apply to   │ Screening Visit This criterion does not apply to   │
│ heterozygous subjects                              │ heterozygous subjects                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Previously randomized and dosed in this study This │ Previously randomized and dosed in this study This │
│ criterion does not apply to heterozygous subjects  │ criterion does not apply to heterozygous subjects  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any other reason which in the opinion of the       │ Any other reason which in the opinion of the       │
│ Investigator would confound proper evaluation of   │ Investigator would confound proper evaluation of   │
│ the study                                          │ the study                                          │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have maximum age of 65 Years │
├───────────────────────────────────┤
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛